Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.46 |
| ▸ | LPL | P06858 | 2/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30149369 | 1.00 | CYP1A2 (0.46) | CYP1A2TSHRCYP2A6LPLLIPG | |
| SCHEMBL30271873 | 0.83 | LPL (0.44) | CYP1A2TSHRCYP2A6LPLLIPG | |
| SCHEMBL20829045 | 0.83 | LPL (0.44) | CYP1A2TSHRCYP2A6LPLLIPG | |
| SCHEMBL21446903 | 0.83 | LPL (0.44) | CYP1A2TSHRCYP2A6LPLLIPG | |
| SCHEMBL23043788 | 0.81 | CYP2A6 (0.44) | CYP1A2TSHRCYP2A6LPLLIPG | |
| SCHEMBL14726957 | 0.81 | CYP1A2 (0.42) | CYP1A2CYP2A6LPLLIPGALDH1A1 | |
| SCHEMBL12148735 | 0.81 | LPL (0.38) | LPLLIPGMAPK1ANPEPLAP3 | |
| SCHEMBL732170 | 0.80 | LPL (0.47) | CYP1A2TSHRCYP2A6LPLLIPG | |
| SCHEMBL26622004 | 0.80 | ALDH1A1 (0.46) | CYP1A2CYP2A6LPLLIPGALDH1A1 | |
| SCHEMBL1335831 | 0.79 | LPL (0.47) | CYP1A2TSHRCYP2A6LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507262-B2 | Compositions for oxidatively dyeing keratin fibers and methods for using such compositions | THE PROCTER & GAMBLE COMPANY (US) | 2009-03-24 | — | — | US | claimed |
| EP-2018146-A2 | COMPOSITIONS FOR OXIDATIVELY DYEING KERATIN FIBERS AND METHODS FOR USING SUCH COMPOSITIONS | The Procter and Gamble Company (US) | 2009-01-28 | — | — | EP | claimed |
| US-20070209123-A1 | Compositions for oxidatively dyeing keratin fibers and methods for using such compositions | THE PROCTER & GAMBLE COMPANY | 2007-09-13 | — | — | US | claimed |
| WO-2007102126-A2 | COMPOSITIONS FOR OXIDATIVELY DYEING KERATIN FIBERS AND METHODS FOR USING SUCH COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2007-09-13 | — | — | WO | claimed |
| EP-3286234-B1 | MULTIMODAL AND BROAD MOLECULAR WEIGHT HIGH DENSITY POLYETHYLENE | EXXONMOBIL CHEMICAL PATENTS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20240150377-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2024-05-09 | — | — | US | disclosed |
| CN-112300214-B | Palladium complex, preparation method thereof and preparation method of axial chiral biaromatic compound | 中国科学院上海有机化学研究所 | 2023-12-12 | — | — | CN | disclosed |
| US-20230382924-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230382924-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| US-20230382924-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| EP-4225765-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4225446-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20090144914-A1 | COMPOSITIONS FOR OXIDATIVELY DYEING KERATIN FIBERS AND METHODS FOR USING SUCH COMPOSITIONS | LIM MU LLL | 2009-06-11 | — | — | US | disclosed |
| US-7507262-B2 | Compositions for oxidatively dyeing keratin fibers and methods for using such compositions | THE PROCTER & GAMBLE COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-20070209123-A1 | Compositions for oxidatively dyeing keratin fibers and methods for using such compositions | THE PROCTER & GAMBLE COMPANY | 2007-09-13 | — | — | US | disclosed |
| EP-1506190-B1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | HOFFMANN LA ROCHE (CH) | 2006-06-14 | — | — | EP | disclosed |
| US-7005432-B2 | Substituted imidazol-pyridazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-02-28 | — | — | US | disclosed |
| EP-1506190-A1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | EVOTEC INTERNATIONAL GMBH (DE) | 2003-12-11 | — | — | US | disclosed |
| WO-2003097637-A1 | (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090144914-A1 | COMPOSITIONS FOR OXIDATIVELY DYEING KERATIN FIBERS AND METHODS FOR USING SUCH COMPOSITIONS | KRT18, AKR7A2, AKR1C4 | CYP1A2 1320/4885TSHR 2810/4885CYP2A6 564/4885 |
| US-20070209123-A1 | Compositions for oxidatively dyeing keratin fibers and methods for using such compositions | KRT18, AKR7A2, AKR1C4 | CYP1A2 1320/4885TSHR 2810/4885CYP2A6 564/4885 |
| US-20030229096-A1 | Substituted imidazol-pyridazine derivatives | GRIN2B, GRIN2A, GRIN2C | CYP1A2 1651/4885TSHR 1122/4885CYP2A6 3453/4885 |
| US-20230382924-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CYP1A2 4613/4885TSHR 1941/4885CYP2A6 3817/4885 |
| US-20240150377-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CYP1A2 4571/4885TSHR 1924/4885CYP2A6 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.